Last quarter (Q2 2022), Innovent Biologics's total revenue was ¥―, a decrease of ― from the same quarter last year. In Q2, Innovent Biologics's net income was ¥―. See Innovent Biologics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	¥ 4.27B	¥ 3.84B	¥ 1.05B	¥ 9.48M	¥ 18.54M
Cost of Revenue	-	¥ 573.04M	¥ 387.76M	¥ 124.88M	¥ 0.00	-
Gross Profit	-	¥ 3.70B	¥ 3.46B	¥ 922.65M	¥ 9.48M	-
Operating Expense	-	¥ 6.05B	¥ 3.50B	¥ 2.20B	¥ 1.56B	¥ 643.27M
Operating Income	-	¥ -2.35B	¥ -42.44M	¥ -1.28B	¥ -1.55B	¥ -624.73M
Net Non Operating Interest Income Expense	-	¥ 89.29M	¥ 47.75M	¥ -59.49M	¥ -48.29M	¥ -49.24M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	¥ -3.05B	¥ -858.71M	¥ -1.72B	¥ -5.87B	¥ -716.05M
Tax Provision	-	¥ 87.04M	¥ 139.71M	¥ 0.00	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	¥ -3.14B	¥ -998.42M	¥ -1.72B	¥ -5.77B	¥ -562.32M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	¥ 6.62B	¥ 3.89B	¥ 2.33B	¥ 1.56B	¥ 643.27M
Net Income From Continuing And Discontinued Operation	-	¥ -3.14B	¥ -998.42M	¥ -1.72B	¥ -5.77B	¥ -562.32M
Normalized Income	-	¥ -3.23B	¥ -1.02B	¥ -1.72B	¥ -1.44B	¥ -549.51M
Interest Expense	-	¥ 62.46M	¥ 68.35M	¥ 59.49M	¥ 68.97M	¥ 57.23M
EBIT	-	¥ -2.99B	¥ -790.36M	¥ -1.66B	¥ -5.80B	¥ -658.83M
EBITDA	-	¥ -2.78B	¥ -704.74M	¥ -1.57B	¥ -5.74B	¥ -597.72M

Currency in CNY

Innovent Biologics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing